18 active not recruiting, 10 completed, 7 recruiting, 6 unknown. 31 Phase 2, 14 Phase 1, 2 Phase 3.
Follow ceralasertib: new trials by email Literature Review of ceralasertib trials Research Report on ceralasertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study Biospecimen Collection, Ceralasertib, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype | Phase 2 | Recruiting | SWOG Cancer Research Network | 900 | 2025-11-06 | 2026-03-30 |
| Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib [14C] AZD6738, AZD6738 / ceralasertib - Neoplasm | Phase 1 | Terminated | AstraZeneca | 2 | 2025-09-22 | 2026-09-03 |
| Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer Biospecimen Collection, Ceralasertib, Computed Tomography - Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 630 | 2025-08-07 | 2026-09-21 |
| Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen Durvalumab (MEDI4736), Ceralasertib, radiotherapy - Non Small Cell Lung Cancer NSCLC | Phase 2 | Recruiting | Mario Negri Institute for Pharmacological Research | 21 | 2025-08-07 | 2025-12-18 |
| A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z Ceralasertib, Drug X, Drug Y - Advanced Solid Tumours | Phase 1 | Terminated | AstraZeneca | 1 | 2025-05-21 | 2026-07-24 |
| A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy Ceralasertib, Durvalumab - Advanced or Metastatic NSCLC | Phase 2 | Active not recruiting | AstraZeneca | 39 | 2023-06-21 | 2026-09-09 |
| Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel Ceralasertib, Durvalumab, Nab-paclitaxel - Triple Negative Breast Cancer Metastatic | Phase 2 | Recruiting | IFOM ETS - The AIRC Institute of Molecular Oncology | 37 | 2022-12-15 | 2025-08-24 |
| A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours Ceralasertib, Durvalumab - Advanced Solid Tumours | Phase 1 | Active not recruiting | AstraZeneca | 14 | 2022-09-23 | 2026-08-11 |
| A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy Ceralasertib, Durvalumab, Docetaxel - Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 3 | Active not recruiting | AstraZeneca | 594 | 2022-09-15 | 2026-07-13 |
| A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition Ceralasertib, Durvalumab - Melanoma | Phase 2 | Active not recruiting | AstraZeneca | 194 | 2022-08-11 | 2025-07-31 |
| An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies Ceralasertib - Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 12 | 2022-06-09 | 2024-08-02 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Biopsy Procedure, Biospecimen Collection, Ceralasertib - Advanced Breast Carcinoma, Advanced Colon Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 51 | 2021-08-09 | 2026-11-18 |
| Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer Cisplatin, Carboplatin, Etoposide - Extensive Stage Small Cell Lung Cancer | Phase 2 | Active not recruiting | Muhammad Furqan | 30 | 2021-04-20 | 2026-09-03 |
| A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC Radiotherapy, Olaparib Oral Tablet [Lynparza], AZD1390 - Non Small Cell Lung Cancer | Phase 1 | Recruiting | University of Leeds | 200 | 2021-03-17 | 2025-12-19 |
| A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer Ceralasertib - Advanced Solid Tumours | Phase 2 | Completed | AstraZeneca | 54 | 2020-12-01 | 2025-08-29 |
| Olaparib With Ceralasertib in Recurrent Osteosarcoma Olaparib, Ceralasertib - Osteosarcoma, Osteosarcoma Recurrent | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 49 | 2020-11-24 | 2026-09-24 |
| A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment. Olaparib, Ceralasertib, Placebo to match olaparib - Ovarian Cancer | Phase 2 | Withdrawn | AstraZeneca | 2020-08-07 | 2021-03-10 | |
| Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer Cediranib, Ceralasertib, Olaparib - Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 60 | 2020-07-28 | 2026-09-14 |
| DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer AZD6738, Durvalumab, Olaparib - Bile Duct Cancer, Chemotherapy Effect | Phase 2 | Unknown | Seoul National University Hospital | 74 | 2020-06-25 | 2024-04-19 |
| AZD6738 Plus Durvalumab in Biliary Tract Cancer AZD6738, Durvalumab - Bile Duct Cancer, Chemotherapy Effect | Phase 2 | Unknown | Seoul National University Hospital | 26 | 2020-06-25 | 2024-04-19 |
Showing 20 of 46. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (7) · Neoplasms (6) · Lung Neoplasms (4) · Triple Negative Breast Neoplasms (4) · Breast Neoplasms (3) · Endometrial Neoplasms (3) · Neoplasm Metastasis (3) · Bile Duct Neoplasms (2) · Carcinosarcoma (2) · Melanoma (2) · Ovarian Neoplasms (2) · Small Cell Lung Carcinoma (2) · Adenocarcinoma (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1)
AstraZeneca (13) · Institute of Cancer Research, United Kingdom (3) · National Cancer Institute (NCI) (3) · Samsung Medical Center (3) · Acerta Pharma BV (2) · M.D. Anderson Cancer Center (2) · Seoul National University Hospital (2) · Assistance Publique Hopitaux De Marseille (1) · CCTU- Cancer Theme (1) · Dana-Farber Cancer Institute (1) · Gordon Mills, MD, PhD (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · IFOM ETS - The AIRC Institute of Molecular Oncology (1) · Joseph Paul Eder (1) · Mario Negri Institute for Pharmacological Research (1)
United States (22) · United Kingdom (15) · South Korea (10) · France (8) · Spain (8) · Italy (7) · Canada (6) · Germany (5) · Poland (5) · Belgium (3) · Netherlands (3) · Taiwan (3) · Australia (2) · China (2) · Hungary (2)
Alastair Greystoke, MB ChB, MSc, PhD (1) · Andrew M Brunner, MD (1) · Andrew Tutt (1) · Andrew Tutt, MB ChB PhD (1) · Anne C Chiang (1) · Banu Arun (1) · Birgit Geoerger, MD (1) · Corinne Faivre-Finn, MD, PhD (1) · Dr Amit Oza, MD (Lon) FRCP FRCPC (1) · Dr. Umamaheshwar Duvvuri (1) · Duncan Jodrell (1) · Dwight H Owen (1) · Fiona Simpkins, MD (1) · Gary W Middleton (1)
PMID 34904813, PMID 31538815, PMID 32379297, PMID 32669708, PMID 32878963, PMID 32919527, PMID 33892407, PMID 33893289, PMID 34347542, PMID 34543871, PMID 35292802, PMID 35790315, PMID 36446040, PMID 37273420, PMID 37934611, PMID 38351187, PMID 40069402, PMID 40525978, PMID 40781023, PMID 41351730, PMID 41686845, PMID 41838385, PMID 42379235, PMID 42518016, PMID 42686334
2016 (3), 2017 (3), 2018 (3), 2014 (1), 2023 (1), U10CA180820 (1), U10CA180888 (1), UM1CA186688 (1), UM1CA186689 (1)